NIH Institute / Center · CA (NCI)
National Cancer Institute
678 funded awards, $510.3M total, FY2023-FY2025.
NIH SBIR/STTR funding decisions are made by Institutes and Centers based on portfolio priorities, NOFO scope, and program officer judgment. Historical funding patterns do not guarantee future funding.
Technology areas funded by NCI
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
Pattern read
NCI has been one of the heaviest SBIR funders by dollar volume in the window: 678 records and $510M. Median award is $825K, the highest among the major ICs, reflecting NCI's willingness to fund larger Phase II awards and Fast-Track in oncology. The portfolio mix is dominated by small-molecule therapeutics, research tools, biomarker development, and therapeutic vaccines. R44 dominates (423 of 678 records). R42 share (71) is notable; NCI funds more STTR Phase II work than most ICs. Concentration is the lowest among the major ICs at 3.1%. NCI's oncology SBIR landscape is genuinely diffuse, and the strong STTR participation reflects heavy academic-cancer-center origin patterns.